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Abstract Sarcoidosis (SA) is a granulomatous, multi-
system disease of unknown etiology. Most often the dis-
ease affects lungs and mediastinal lymph nodes, but it may
occur in other organs. Neurosarcoidosis (NS) more com-
monly occurs with other sarcoidosis forms, in 1 % of cases
it involves only nervous system. Symptomatic NS occurs
but on autopsy study up to 25 % of cases are confirmed. NS
can affect central nervous system: the brain, spinal cord
and peripheral nerves, and muscles. The diagnosis of
neurosarcoidosis facilitates diagnostic criteria: histopa-
thological, imaging and cerebrospinal fluid examination,
and clinical symptoms. At present, there are no set stan-
dards for treatment of patients suffering from NS. Early
therapy of symptomatic patients is recommended. Corti-
costeroids still are the first line of treatment for NS
patients. In cases of steroids resistance, lack of their
effectiveness or existence of contraindication to their use,
immunosuppressant treatment is recommended. The latest
NS algorithm with immunosuppressive treatment is
discussed.
Keywords Neurosarcoidosis  Neurosarcoidosis forms 
Clinical symptoms  Diagnosis  Treatment
Introduction
Sarcoidosis (SA) is a multisystem disorder of unknown
cause [1–15]. In the light of the modified Matzinger’s
model of immune response [8] and results of studies con-
ducted by Dubaniewicz et al. [reviewed in 7] and other
researchers [reviewed in 7, 9–15], human heat shock pro-
teins (HSPs) as main ‘danger signals’ (tissue damage-
associated molecular patterns-DAMPs) and/or microbial
HSPs as pathogen-associated molecular patterns (PAMPs)
recognized by pattern recognition receptors (PRR), may
induce sarcoid inflammation (lymphocytes CD4 in excess
of CD8 in affected organs with an insufficient number and/
or function of CD4 cells within the blood) by both infec-
tious and non-infectious factors in a genetically differently
predisposed host (Fig. 1) [reviewed in 1, 7].
SA most frequently occurs in Northern Europe, Japan and in
central USA and its eastern coast, particularly in adults about
30–40 years old and in older adults, especially in women
(Fig. 1) [1–6]. Among Afro-Americans, SA occurs * 4 times
more frequently than among Caucasians or Asians, and it is as
a rule of a more advanced process in character. The risk of
death from SA is estimated at 1–5 % and connected with
respiratory insufficiency in Europe and the USA, whilst in
Japan the cause of death is from the cardiac form of SA.
Previous limited epidemiological data in Poland puts the rate of
disease from SA at about 10 in 100,000 inhabitants [5].
Due to the unknown etiology of sarcoidosis and a lack of
specific diagnostic tests the diagnosis of SA relies on
clinical and radiological examinations and confirmed histo-
pathological biopsy results of the organ affected by the
disease process, which identify the characteristic nonca-
seating granuloma (in about 80 %) following the exclusion
of other causes of granuloma formation, primarily tuber-
culosis [1–6].
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Imaging is an effective method of diagnosis, such as
chest X-ray (CXR), high resolution computer tomography
(HRCT), magnetic resonance with gadolinium (MRI) and/
or positron emission tomography with fluorodeoxyglucose
(FDG-PET) [1–8, 16–18]. Less effective in diagnosis are
radioisotope methods (using Tall 201, Gal67, 99 m-Tc),
which show defect of perfusion, which after eliminating
circulatory insufficiency disease, can be a relevant indica-
tor in diagnosis.
The most helpful diagnostic tool in pulmonary SA has
turned out to be a bronchoalveolar lavage (BAL) in the
presence of cellular composition. An increase index of
lymphocytes CD4/CD8 greater than 3.5 indicates an active
sarcoidosis process. Some centers emphasize the high
diagnostic value of increased expression of integrin
CD103, a differentiating antigen in immunological cells,
including in BAL fluid the CD103?CD4?/CD?4
ratio \ 0.2, CD4/CD8 [ 3, CD4?/CD8? BALF/peripheral
blood [ 2 [reviewed in 1–6].
Other tests helpful in the diagnosis of SA include: an
elevated concentration of calcium in both blood and urine,
a complete blood count with often lymphopenia, liver
function tests, increased CRP, immunoglobulin G, level of
soluble receptor for IL-2 (sIL-2R) and neopterin. The high
concentration of serum angiotensin-converting enzyme
(ACE) present in only 24–76 % of SA patients can also be
present in tuberculosis and neoplasm, therefore, the diag-
nostic value is limited. It is mostly useful in diagnosing
sarcoidosis of the cerebrospinal meninges or in monitoring
the course and treatment of this disease [19, 20]. In a few
states in the USA, the Kveim-Sitzbach test is also used to
diagnose SA [1].
The clinical course of SA can be symptomless, where
sarcoidosis is discovered accidentally during a routine
examination to diagnose some other diseases or symp-
toms. SA patients with an acute stage of disease often
complain of symptoms connected with Lo¨fgren‘s syn-
drome (bilateral hilar lymphadenopathy, arthritis, ery-
thema nodosum with/without a high temperature). In
30 % of sufferers, after 2 years it takes on the chronic
form with a cough, breathlessness, and respiratory
insufficiency [1–6].
Fig. 1 The etiopathogenesis of sarcoidosis
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The most frequent form of this disease in Europe and
USA is sarcoidosis of the respiratory system, although
many other forms exist (Table 1) [1–6]. Extrapulmonary
sarcoidosis may coexist with pulmonary SA, can overtake
it or occur following remission of the pulmonary form,
sometimes after several years (Table 1) [20–33]. There-
fore, all patients with sarcoidosis should have pulmonary,
ophthalmic, cardiac, skin, neurological, and abdominal
organs examinations as well as radiological, EKG/ECHO,
and laboratory tests to detect pulmonary and/or extrapul-
monary manifestations of the disease [20].
To life-threatening forms of extrapulmonary sarcoidosis
belong ocular SA, cardiac SA, and the nervous system SA.
Sarcoidosis of the nervous system
(neurosarcoidosis—NS)
The first case of neurosarcoidosis was described by
Winkler in 1905 [reviewed in 28]. Similarly, as in car-
diac sarcoidosis, NS appears symptomatically in about
5–10 % of cases, but up to 25 % are indicated from
postmortem [6, 20–33]. A case control etiologic study of
sarcoidosis (ACCESS) showed that neurosarcoidosis was
more common in females than in males (6.0 vs. 2.2 %)
[6]. The usual mean age of onset is from 33 to 41 years,
slightly later compared to other forms of SA [reviewed
in 30].
Table 1 The occurrence of forms of sracoidosis (SA) [reviewed in 1, 20]
Forms of sarcoidosis Occurrence (in %)
Pulmonary sarcoidosis
Respiratory system
a possible spontaneous remission in stages I–III of SA: stage I—bilateral hilar lymphadenopathy, stage II—
lymph-adenopathy and diffuse pulmonary infiltrations, stage III—diffuse pulmonary infiltrations with
fibrosis only in lung parenchyma, stage IV—irreversible fibro-cavernous changes in the lungs; bronchial






Nervous system 5–15—symptomatic, 25—on
autopsy
Heart
arrhythmia, sudden death (SA in ventricular septum often affects the cardiac conduction system), myocarditis,
pericarditis with/without pericardial effusion, mitral regurgitation, congestive heart failure, myocardial




anterior uveitis (50–90 %), intermediate uveitis, posterior uveitis with retinal perivasculitis, periphlebitis,
neovascularization, vitreous hemorrhage, proliferative retinopathy, conjunctivitis, orbital mass lesions,




lytic/sclerotic changes in bone (e.g. skull, nasal bones, vertebrae), jungling’s syndrome (cystic spreading of
the short bones of the hand and foot), acute and chronic arthritis
5–40
Skin
erythema nodosum, lupus pernio, macules, papules, sub-cutaneous nodules, plaques, ichthyosis, ulcers,







keratoconjunctivitis sicca syndrome, proptosis
15–28, but up to 88 % on Gal67
scanning
Parotid glands
Heerfordt’s syndrome (fever, uveitis, inflammation of lacrimal and parotid glands, paresis n. VII), Mikulicz’s
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Neurosarcoidosis can appear with other forms of SA,
e.g. pulmonary (in about 88–94 %), ocular SA (in
37–55 %) and SA of the skin (in 30 %), or it can be iso-
lated, in about 1 % and limited only to the nervous system
[25]. The course of NS is most frequently acute or subacute
and in about 30 % of cases, leads to the chronic phase [27].
NS may also affect the central nervous system: the
brain, spinal cord and peripheral nerves and muscles [6,
20–33]. Early NS manifestation often presents with
sarcoid granuloma in the central nervous system and
later may affect the peripheral nervous system and
muscles [22]. Considerable diagnostic problems are
caused by isolated, disseminated forms as well as
symptomless or subclinical NS. Neurosarcoidosis also
coexists with other neurological diseases e.g. demye-
linating processes, vascular disorders or neuroborreliosis
frequently making diagnosis difficult [21, 25, 33, 34].
Presently two sets of criteria have been proposed for
identifying NS. In accordance with Zajicek [29], neu-
rosarcoidosis can be defined as follows:
• Confirmed NS—the clinical picture suggests NS, other
causes of neurological symptoms have been excluded,
there is a histopathological presence of characteristic
granuloma in the biopsy material in the central nervous
system.
• Probable NS—the clinical picture suggests NS, other
causes of neurological symptoms have been excluded,
changes noted in an MRI scan indicate the presence of
NS, the presence of an increased level of protein and/or
pleocytosis particular lymphocytic, as well as the
presence of oligoclonal bands confirmed in the cere-
brospinal fluid, where the presence of systemic sar-
coidosis has been confirmed histopathologically, or
there have been at least 2 imaging results (Gal67
scintigraphy, CXR), there is an increased level of ACE
in serum.
• Possible NS—the clinical picture suggests NS and other
causes of neurological symptoms have been excluded.
According to Judson et al. [6], the criteria are as follows:
• Confirmed NS—the patient suffering SA presents
symptoms of diabetes insipidus, paresis of the facial
nerve, an MRI head scan (with gadolinium contrast)
confirms changes in the cerebrospinal meninges or the
brain stem, in the cerebrospinal fluid are increased
levels of cells, particularly, lymphocytes and/or
increased protein, a biopsy of nerve tissue reveals
granulomas inflammation.
• Probable NS—neuropathy of undefined cause appears
in the patient, MRI confirms abnormalities other than
those defined above, electrodiagnostic tests show
abnormal results.
• Possible NS—a patient suffering multiorgan SA
presents with unexplained headaches and/or
radiculopathy.
Recently, Marangoni et al. [35] proposed some modifi-
cation to the proposals of Zajicek [29]. Instead of the tra-
ditional CXR, they suggest HRTC and instead of
measuring of ACE level in serum, they propose an evalu-
ation of the CD4/CD8 T cell ratio [ 3.5 in BALF and
CD4/CD8 [ 5 in the cerebrospinal fluid.
Sarcoidosis of the central nervous system (CNS)
Aggressive and/or scattered sarcoid changes in the CNS
appear as small or large nodules and can be the cause of
neurological symptoms, depending on their location [26].
NS can most often appear in the cerebral meninges, espe-
cially leptomeninges, with a tendency to localize at the
base of the brain, in white matter, intraventricular epithe-
lium, chorioidea, and vessel walls supplying the nervous
system [27]. Supratentoral sarcoid granulomas are more
frequent than subtentoral [26].
Cerebral NS
In adults suffering from NS, the rates of sarcoid inflam-
mation in the specific parts of the brain are as follows:
• Cranial neuropathy (brain base)—in about 23–73 %
[30]
– Paresis of n. VII—usually one-side (in 25–50 %),
rarely both sides
– Damage of n. II—blurred vision, abnormal color
recognition, disturbed field of vision, papilledema
in the fundus of the eye (in 1–10 %)
– Damage of n. VIII—deafness, dizziness (in 7 %)
– Damage of n. IX and X—dysfunction of the throat
muscles, palate and vocal chords (in 4 %).
• Brain tumors (effect of mass)—in about 35–50 % [30,
32]
• Disseminated changes—in 30 % [32]
• Aseptic meningitis—in 8–40 % [30]
• Endocrinal disturbance of the hypothalamus and
hypophysis in the course of NS (in 2–26 %) with
primarily diabetes insipidus, polydipsia and polyuria,
galactorrhoea, and amenorrhoea [30]
Cerebral NS is characterized by its wide spectrum of
nonspecific general symptoms such as headache, fatigue,
dizziness, fever or subfever. NS can also be accompanied
by mood swings such as euphoria or depression, disturbed
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behavior e.g. aggression, apathy or symptoms of dementia,
hallucinations or delusions [6, 20–33]. In clinical tests of
those patients however, the most frequent symptom is
isolated cranial neuropathy, which usually has an aggres-
sive course in contrast to multi neural neuropathy of
chronic course. Both types are characterized by good
prognosis [23, 24]. In 5–38 %, NS can be a cause of (non)
communicative hydrocephalus, which is usually chronic
with very poor prognosis and may be the cause of death in
up to 75 % of cases. Epileptic seizures generalized and
partial and simple or complex appear in up to 15 % of
patients with NS and can be connected with poor prognosis
of the disease [21, 36]. However, the rates are different
among children. Epileptic seizures occur and symptoms
connected with the effect of cerebral NS predominantly
occur, whilst cranial neuropathy is rare [37].
Useful in the diagnosis of cerebral NS are:
• Cerebro-spinal fluid examination—changes are fre-
quent (in about 2/3 cases) but unspecific and appear
mainly in cranial neuropathy or meningitis [38]; there is
often mild or moderate lymphocytosis with increased
index of lymphocytes C4/CD8 [ 5, increased protein
concentration, a hypoglycorrhachia with CSF glucose
less than 50 % of concomitant blood glucose (in
10–20 %), increased level of ACE (in about 50 %),
increased IgG level, and uncharacteristic oligoclonal
bands (in about 30 %) [19, 21, 34, 37]; pleocytosis and
hypoglycemia often appear in the acute phase of the
disease [34]; in NS, patients with an isolated cranial
neuropathy of nerve VII, cerebrospinal fluid is mostly
normal [37].
• Imaging methods (CT, MRI brain scan with gadolin-
ium, Gal67 scintigraphy and FDG-PET) [18, 20, 30, 35,
39–47]
– MRI—is considered the most sensitive but unspe-
cific test in diagnosis patients with NS (Fig. 2) [23,
36, 38, 39, 45]; the most common brain MRI
finding of NS is a basilar leptomeningeal involve-
ment (in about 30–40 %), which is usually occurred
as a thickening and diffuse or nodular enhancement;
brain NS in MRI can be also present as focal masses
or diffuse thickening of dural meninges, persistent
pseudotumor changes (in about 14 %); involvement
of hypothalamus/pituitary and cranial nerves, which
show enhancement and thickening post gadolinium;
rarely NS changes in MRI occur as hydrocephalus
or in the periventricular region and in the white
matter.
– Gal67 scintigraphy—in 2/3 of patients changes can
be revealed, however, in the majority they are
unspecific; one characteristic image in scintigraphy,
but also in FDG-PET, observed in sarcoidosis of the
parotid and lacrimal glands is called a ‘‘panda sign’’
[45].
– FDG-PET—allows for a localization of changes in
whole body and finding a characteristic intratho-
racic pattern and/or ‘‘panda sign’’ may be highly
suggestive for sarcoidosis; isolated NS needs addi-
tional diagnostic tests, because FDG-PET does not
distinguish the changes in the course of malignancy
or TB from NS [16, 40–47]; recently, it was
revealed that a combination multiple fluorodeoxy-
glucose PET-avid lymph nodes with mild flurot-
hymidine (FLT) PET uptake can be helpful in
differentiating granulomatous inflammatory dis-
eases such neurosarcoidosis from malignancy
[42]; FDG-PET and FLT-PET are more useful
methods in localizing the optimum site for a biopsy
than Gal67 scintigraphy and MRI [37, 42].
• Neurophysiological tests—the effectiveness of a visual
evoked potentials (VEPs) test is recommended partic-
ularly, as an affected optic nerve can be symptomatic of
NS, and also auditory evoked potentials (AEPs) with
abnormal results suggested NS changes in the brain
stem, precursory subclinical or clinical manifestations;
equally VEP and AEPs are useful in monitoring the
progress of the disease [21, 25]; the advantage of such
tests are that they are noninvasive, do not require prior
preparation of the patient, are simple to carry out and
can be repeated.
• A biopsy of the cerebrospinal meninges or brain
remains the gold standard for the diagnosis of NS; in
the case of negative results of the biopsy or the
Fig. 2 Neurosarcoidosis in MRI brain in sagital plane: T1-weighted
contrast-enhanced MR image shows basal leptomeningeal enhance-
ment and an extensive enhancement of the pituitary gland and stalk,
which is markedly enlarged
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existence of contraindication to its use, a tissue
diagnosis of sarcoidosis can often be established in
an extraneural location, e.g. biopsy of lymph nodes,
lungs, conjunctiva or lacrimal/parotid glands
(Table 1) [6, 20–33].
Sarcoidosis of the spinal cord
The spinal form of NS, of long duration appears in about
4–28 % of cases more often in old age and prognosis is
poor [30, 32]. Sarcoid changes can be located intra- or
extramedullary (intra or extra meninges). According
to Junger et al. [48] the spinal form occurs in four
stages:
1. Leptomeningeal enhancement
2. Fusiform spinal cord enlargement
3. Focal or diffuse intramedullary disease
4. Spinal cord atrophy
Most frequently stages 2 and 3 occur in this form of
NS, according to cited authors. In a recent case series of
29 patients with spinal cord neurosarcoidosis revealed
that lesions were mostly intramedullary (in 81 %),
although in 48 % involved the leptomeninges [49].
Spinal SA is mostly revealed by back pain of radicular
type, weakness and paresthesias of limbs may also occur
[32]. An MRI scan is useful, where the spinal NS appears
as an enhancement, a thickening of leptomeninges,
fusiform thickening of the spinal cord, most often in the
thoracic level or cervical, affecting three or more spinal
segments (Fig. 3) [45, 49].
Peripheral nervous system SA (PNS)
Acute or chronic peripheral neuropathy occurs in about
2–40 % of patients with NS [30]. Patients with NS from the
Caucasian population are confirmed as having a greater
predisposition to PNS than Afro-Americans. The most
common form is symmetrical axonal sensory motor poly-
neuropathy, rare is demyelinating form, focal mononeu-
ropathy, multi focal, polyradiculopthy or vascular
neuropathy [21].
In PNS, the large nerve fibers are often affected (large
fiber neuropathy—LFN) appearing as a disturbance of
proprioceptive sensation and vibration. At a microscopic
level sarcoid granulomas locate themselves in the peri-
neurium and epineurium, while the endoneurium is mostly
spared. The most useful diagnostic test is an electroneu-
rography with a typically low amplitude of muscle
response—M during stimulation of the nerve. This form of
neuropathy has a mostly acute or subacute course and
usually is associated with a good prognosis.
Rarer with a poor prognosis is a small fiber neuropathy
(SFN) with disturbed senses of pain and temperature as
well as frequently changed autonomic functions. SFN
involves the small thinly myelinated (A delta) and unmy-
elinated (C), and autonomic nerve fibers due to axon loss or
oxidative stress [25]. A high risk of developing SFN is also
associated with an increased frequency in the occurrence of
HLA-DQB1*0602 antigen and/or non-HLA polymorphic
genes encoded proinflammatory cytokines, particularly in
patients with advanced disease process. It is symptomized
by burning pain, paresthesia, restless legs syndrome,
reduced perspiration, skin dryness and disturbed blood
circulation [25]. In contrast to LFN, a biopsy of skin with
Fig. 3 Neurosarcoidosis in MRI cervical spine in sagital plane: T1-weighted contrast-enhanced MR image shows enhancing leptomeningeal
lesions involving of the spinal cord
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reduced intraepidermal nerve fiber density is essential in
diagnosing of SFN.
Muscle sarcoidosis
In muscles, sarcoid granuloma may locate between nerve
fibers. Muscle sarcoidsis is mostly diagnosed asymptom-
atically, however, about 1 % of patients present with side
effects such as pain, weakened muscle or atrophy [30]. The
course of this form can be acute or subacute. In the labo-
ratory blood tests often confirm an increased level of
muscle enzymes such as phosphocreatine kinase (CPK),
AspAT, also hyperkalemia and an increased level of ACE
(30–40 %), sIL-2R. In an electromyography test a myo-
genic pattern is characteristic. Imaging tests are also
helpful e.g. scintigraphy with Gal and FDG-PET. However,
a biopsy from the affected muscle is the best diagnostic
test.
NS treatment
At present there are no set standards for the treatment of
patients suffering from NS [1, 20–23, 30, 36, 49–61]. Most
treatment recommendations derive from expert opinion
from centers seeing several dozen cases annually, from
case reports or from small uncontrolled case series
[reviewed in 30, 36, 57]. The majority of authors recom-
mend early symptomatic treatment of patients. Nozaki and
Judson [36] suggested that specific treatment for NS needs
to be given over 6 months and tapering of medications
should be individualized based on the seriousness of the
illness, response to the treatment, and toxicity of therapy.
Relapses are common and may occur in 20–50 % cases
following discontinuation of the treatment. Thus, many
patients with recurrent relapses need treatment for pro-
longed periods, sometimes for years [59].
Pharmacologic treatment
• Corticosteroids are considered the drug of choice for
the treatment of sarcoidosis with monitoring for
potential adverse events, e.g. peptic ulcer diseases,
systemic fungal infection, active tuberculosis, hyper-
sensitivity, cataract formation, diabetes mellitus or
osteoporosis [reviewed in 1, 20–23, 30, 36, 51, 53, 59]:
– The cranial neuropathy: according to the latest
treatment algorithm for NS, proposed by Nozaki
et al. (with input from personal communication from
Professors Barney Stern and Robert P. Baughman)
[36] in 2013, in the case of cranial neuropathy,
particularly where nerve VII is affected, prednisone is
recommended in a daily dose of 20-40 mg with a
decrease of dosage over 1–6 months to the lowest
effective dose; if corticosteroids cannot be tapered to
less than 10 mg/day of prednisone equivalent within
3–6 months, consideration should be given to higher
dose prednisone and/or alternative agents [51]; there
was a tendency for recurrence of symptoms at doses
of prednisone less than 20–25 mg/day [reviewed in 1,
36, 51].
– The mild or moderate NS, usually initiate with
20–60 mg/day (prednisone or prednisone equiva-
lent) with a decrease of dosage to the lowest
effective dose; if corticosteroids cannot be tapered
to less than 10 mg/day of prednisone equivalent
within 3–6 months, consideration should be given
to higher dose prednisone and/or alternative agents
[reviewed in 20, 36].
– The severe NS (e.g. altered sensorium, visual loss,
or weakness), cases not responding to oral agents,
and refractory NS: the administration of intrave-
nous methylprednisolone is advised, at 1 g daily for
3–5 days followed by 1 g per week or daily
prednisone orally with a decrease of dosage to the
lowest effective dose [reviewed in 36].
• Immunomodulating and cytotoxic agents such as
methotrexate, cyclosporine, cyclophosphamide, or
azathioprine
– Methotrexate (MTX)—is used as a first-line corti-
costeroid-sparing agent and allows tapering of
prednisone dose to 10 or 20 mg/day in more than
one-third of NS cases [reviewed in 36, 51]; it is also
reported a beneficial response to MTX in approx-
imately one-fifth of NS patients, who failed pred-
nisone monotherapy [52]; a combination of
corticosteroids and MTX has resulted in a favorable
outcome in patients with severe CNS involvement
[reviewed in 36]; the effectiveness of MTX, given
orally, mostly in an initial dose of 7.5 mg/per week
and then 10–20 mg/week is noted in about 60 % of
NS patients [27]; it requires monitoring for adverse
events, e.g. hepatotoxicity, renal insufficiency,
pneumonitis, teratogenicity, bone marrow suppres-
sion; an administration of folinic acid may reduce
toxicity [reviewed in 36].
– Azathioprine—has been used for corticosteroid-
refractory NS with potential adverse effects, like
neutropenia, abnormal liver function tests, pancre-
atitis or allergic reactions [reviewed in 30, 55–57];
usual oral dose of azathioprine is 2–3 mg/kg
[reviewed in 57].
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– Cyclosporine—it was beneficial in some patients,
who failed prednisone monotherapy; others wors-
ened in spite of a combination of cyclosporine and
corticosteroid therapy [28]; it can be started at
4 mg/kg/day in divided doses and requires moni-
toring for adverse events, e.g. hypertension, renal
failure, hypomagnesemia, and neurotoxicity
[reviewed in 30].
– Cyclophosphamide—due to its high toxicity and
significant side effects (bone marrow suppression,
teratogenicity and carcinogenicity), the use of it is
usually limited to severe NS, when TNF-a antag-
onist cannot be obtained, in NS refractory to other
agents; it is also corticosteroid-sparing agent in NS
and allows tapering of prednisone dose to 10 mg
[52, 53]; according to authors [53, 54], dose of
cyclophosphamide is 500–1000 mg intravenously
over 30–60 min every 2–4 weeks or 0.5 g/m2 of
body surface area intravenously every 4 weeks
depending on age, leukocyte count or renal func-
tion; given orally, an initial dose 25–50 mg/day is
increased by 25 mg increments to ensure adequate
immunosuppression; the maximum oral dose is
150 mg/day; intravenous administration of cyclo-
phosphamide is preferred over oral administration
due to a lesser side effects [54].
– Mycophenalate mofetil—immunosuppressant as an
analog of methotrexate is considered for patients
with central NS, though not effective in NS of the
muscles [reviewed in 36].
– Anti-malarial agents, like chloroquine and hydrox-
ychloroquine have anti-inflammatory effects and
they are also effective in sarcoidosis, especially in
patients with NS and sarcoidosis-induced hypercal-
cemia and/or sarcoid skin lesions; its standard oral
dosage is 250–750 mg daily; hydroxychloroquine
has lower risk of ocular toxicity than chloroquine,
but is less effective than chloroquine; because
hydroxychloroquine reduces serum glucose levels,
it may be useful for NS patients with steroid-
induced hyperglycemia; its standard dosage is
200–400 mg daily orally [20, 21, 36, 57, 59].
– A tumor necrosis factor alpha (TNF-a) inhibitor—
e.g. infliximab, adalimumab, thalidomide, pentox-
ifylline: infliximab is commonly used for neurosar-
coidosis that is refractory to other agents and/or
corticosteroid-induced complications; in a recent
case series of 29 patients with spinal cord neuro-
sarcoidosis, infliximab was the second most fre-
quently used immunosuppressive agent after
corticosteroids [49]; it is also useful for therapy of
SFN [30, 50, 51]; infliximab 3–5 mg/kg intrave-
nously every 4–8 weeks; often, patients receive an
initial loading dose of 3–5 mg/kg intravenously at
weeks 0, 2, and 6 [reviewed in 36]; adalimumab and
teratogenic thalidomide are effective especially for
spinal forms of NS [30, 36, 50, 51, 58]; pentoxif-
ylline have been shown to be effective for various
types of organ involvement from systemic sarcoid-
osis, however, their role in the treatment of
neurosarcoidosis is unknown [reviewed in 36, 57];
several major toxicities are encountered with the
anti-TNF therapies, but one of the more serious
concerns is the increased risk of tuberculosis and
similar infections [36, 49, 57].
• Treatment of associated conditions
In addition to specific treatment for sarcoidosis, treatment
for associated conditions (e.g., anti-epileptics, medicines
for neuropathic pain or hormonal replacement therapy in a
neuroendocrine dysfunction) may be required for the
treatment of neurosarcoidosis [20, 21, 30, 36, 50, 51].
Neurosurgical treatment
Patients with NS, who qualify for neurosurgery are those
with hydrocephalus (a ventricle-peritoneum shunt is
inserted), pseudotumor forms with the mass effect in the
brain and spinal cord (resection of changes) [36].
Radiotherapy
In the case of a lack of response to pharmacological
treatment or a contraindication to surgical procedure, a
cerebral radiotherapy is also recommended [reviewed in
30, 36, 61, 62]. Bruns et al. [61] revealed a partial
resolution of the clinical features and stabilization of
NS after low-dose whole-brain irradiation of the iso-
lated CNS lesion with 20 Gy. Also Chapelon et al. [62]
introduced a patient with sarcoid meningitis, who was
sensitive to radiotherapy and recovered after 200 rads,
whereas NS patients with hemiparesis, an extrapyrami-
dal syndrome, and severe psychiatric features unre-
sponsive to steroids, improved after 6,000 rads.
Radiotherapy (1.3–3.6 Gy/day for 3–24 weeks) was also
beneficial in one of the three patients treated by Ag-
bogu et al. [53].
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